Glenmark Pharmaceuticals is considering partnerships for both its GBR310 omalizumab biosimilar candidate and its Ryaltris (olopatadine/mometasone) nasal spray that is due for a US approval decision within the next few days.
Glenmark Ponders Partners For Omalizumab And Ryaltris Spray
To help fund Phase III clinical trials and US sales and marketing efforts respectively, Glenmark is looking for partners for both its omalizumab biosimilar candidate and its Ryaltris olopatadine and mometasone combination spray.
